Crooke / Prestayko Antineoplastic Agents

1. Auflage 2013
ISBN: 978-1-4832-6791-3
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 414 Seiten, Web PDF

Cancer and Chemotherapy, Volume III: Antineoplastic Agents is a collection of articles that deals with the treatment of cancer using drugs. The collection describes the various drugs that are used, the therapeutic approaches being taken, and agents that are being developed. Part I is a general review of anti-cancer drugs as regards their action mechanisms, pharmacokinetics, pharmacology, known toxicities, and clinical utility. These drugs include alkylating agents such as mitomycin C and nitrosoureas; plant alkaloids such as maytansine; antibiotics such as anthracyclines; platinum-containing complexes; antimetabolites; and hormones. Part II examines the molecular pharmacology of some major drug classes, namely, bleomycin and anthracycline. The text also discusses the chemistry, mechanism, and any structure-activity relationships found in these drug classes. Part III discusses in detail the clinical pharmacology of some antitumor drugs, for example, cisplatin and nitrosoureas. The text includes the clinical applications, biochemistry, metabolism, and the use of mathematical models in interpreting or describing resulting data. The book is helpful for pharmacologists, molecular biologists, and scientists involved in cancer-research.

Autoren/Hrsg.

Crooke, Stanley T.

Prestayko, Archie W.

Inhaltsverzeichnis

1;Front Cover;1
2;Antineoplastic Agents;4
3;Copyright Page;5
4;Table of Contents;6
5;General Preface;14
6;Preface to Volume III;16
7;Part I: General Reviews;18
7.1;CHAPTER 1. NUCLEOSIDE ANALOGUES;20
7.1.1;I. INTRODUCTION;20
7.1.2;II. CYTOSINE ARABINOSIDE;21
7.1.3;III. 5-AZACYTIDINE;25
7.1.4;IV. 5-FLUOROURACIL;26
7.1.5;V. OTHER 5-FLUORO PYRIMIDINES;32
7.1.6;VI. 3-DEAZAURIDINE;33
7.1.7;VII. PURINE ANALOGUES;34
7.1.8;VIII. ARABINOSYL ADENINE;37
7.1.9;REFERENCES;38
7.2;CHAPTER 2. CYCLOPHOSPHAMIDE AND ANALOGUES;42
7.2.1;I. INTRODUCTION;42
7.2.2;II. STRUCTURE AND METABOLISM;42
7.2.3;III. CLINICAL PHARMACOLOGY;44
7.2.4;IV. TOXICITIES;48
7.2.5;V. CLINICAL ACTIVITY AND DOSE SCHEDULES;51
7.2.6;VI. ANALOGUES;51
7.2.7;REFERENCES;52
7.3;CHAPTER 3. NITROSOUREAS;54
7.3.1;I. INTRODUCTION;54
7.3.2;II. DECOMPOSITION AND METABOLISM;55
7.3.3;III. MECHANISM OF ACTION;56
7.3.4;IV. CLINICAL USE;58
7.3.5;V. CLINICAL TOXICITIES;61
7.3.6;REFERENCES;64
7.4;CHAPTER 4. MITOMYCIN C—AN OVERVIEW;66
7.4.1;I. INTRODUCTION;66
7.4.2;II. CHEMISTRY;67
7.4.3;III. STRUCTURE-ACTIVITY RELATIONSHIPS;67
7.4.4;IV. MOLECULAR PHARMACOLOGY;68
7.4.5;V. PHARMACOLOGY;70
7.4.6;VI. CLINICAL EFFECTS;71
7.4.7;VII. CONCLUSIONS;75
7.4.8;REFERENCES;75
7.5;CHAPTER 5. OTHER ALKYLATING AGENTS;78
7.5.1;I. INTRODUCTION;78
7.5.2;II. MECHANISM OF ACTION;80
7.5.3;III. OTHER ALKYLATING AGENTS;82
7.5.4;IV. CONCLUSIONS;91
7.5.5;REFERENCES;92
7.6;CHAPTER 6. THE VINCA ALKALOIDS AND SIMILAR COMPOUNDS;96
7.6.1;I. THE VINCA ALKALOIDS;96
7.6.2;II. THE PODOPHYLLOTOXIN DERIVATIVES;108
7.6.3;III. MAYTANSINE;111
7.6.4;REFERENCES;112
7.7;CHAPTER 7. BLEOMYCIN—AN OVERVIEW;114
7.7.1;I. INTRODUCTION;114
7.7.2;II. CHEMISTRY;114
7.7.3;III. MOLECULAR PHARMACOLOGY;116
7.7.4;IV. CLINICAL PHARMACOLOGY;117
7.7.5;V. CLINICAL ACTIVITIES;119
7.7.6;VI. CLINICAL TOXICITIES;121
7.7.7;VII. CONCLUSIONS;124
7.7.8;REFERENCES;124
7.8;CHAPTER 8. THE ANTHRACYCLINES;128
7.8.1;I. INTRODUCTION;129
7.8.2;II. CHEMISTRY;129
7.8.3;III. MOLECULAR PHARMACOLOGY;130
7.8.4;IV. CLINICAL PHARMACOLOGY;134
7.8.5;V. CLINICAL ACTIVITIES OF ADRIAMYCIN AND DAUNORUBICIN;137
7.8.6;VI. TOXICITIES OF ADRIAMYCIN;140
7.8.7;VII. ANTHRACYCLINES IN DEVELOPMENT;142
7.8.8;REFERENCES;145
7.9;CHAPTER 9. CISPLATIN AND ANALOGUES: A NEW CLASS OF ANTICANCER DRUGS;150
7.9.1;I. INTRODUCTION;150
7.9.2;II. ANTITUMOR ACTIVITY IN ANIMAL TUMORS;151
7.9.3;III. ANIMAL TOXICOLOGY;151
7.9.4;IV. EFFICACY;153
7.9.5;V. TOXICITY;164
7.9.6;VI. CISPLATIN ANALOGUES;167
7.9.7;VII. CONCLUSION;167
7.9.8;REFERENCES;167
7.10;CHAPTER 10. INVESTIGATIONAL CANCER DRUGS;172
7.10.1;I. INTRODUCTION;173
7.10.2;II. ALKYLATING AGENTS;173
7.10.3;III. ANTHRACYCLINE ANALOGUES;176
7.10.4;IV. TUBULIN BINDING AGENTS;177
7.10.5;V. ANTITUMOR ANTIBIOTICS;180
7.10.6;VI. NITROSOUREAS;183
7.10.7;VII. ANTIMETABOLITES;185
7.10.8;VIII. MISCELLANEOUS;188
7.10.9;IX. SUMMARY;191
7.10.10;REFERENCES;197
7.11;CHAPTER 11. HORMONE THERAPY;204
7.11.1;I. BASIS OF ENDOCRINE THERAPY;204
7.11.2;II. PROSTATIC CANCER;206
7.11.3;III. BREAST CANCER;209
7.11.4;IV. CANCER OF THE UTERINE ENDOMETRIUM;217
7.11.5;V. LYMPHOMAS;218
7.11.6;VI. SUMMARY;219
7.11.7;REFERENCES;220
7.12;CHAPTER 12. A HUMAN TUMOR STEM CELL SYSTEM: CONCEPTS, METHODOLOGY, AND APPLICATION;224
7.12.1;I. INTRODUCTION;224
7.12.2;II. METHODOLOGY;227
7.12.3;III. APPLICATIONS;230
7.12.4;IV. CONCLUSIONS;233
7.12.5;REFERENCES;234
8;Part II: Molecular Pharmacology of Selected Antineoplastic Agents;236
8.1;CHAPTER 13. THE MOLECULAR PHARMACOLOGY OF BLEOMYCIN;238
8.1.1;I. INTRODUCTION;238
8.1.2;II. CHEMISTRY;239
8.1.3;III. THE INTERACTIONS OF METALS WITH BLEOMYCIN AND ANALOGUES;239
8.1.4;IV. EFFECTS OF BLEOMYCIN ON ISOLATED DNA;242
8.1.5;V. CELLULAR EFFECTS;245
8.1.6;VI. EFFECTS ON THE CELL CYCLE;246
8.1.7;VIL MORPHOLOGICAL EFFECTS;246
8.1.8;Vili. INTRACELLULAR FATE AND METABOLISM;247
8.1.9;IX. CONCLUSIONS;247
8.1.10;REFERENCES;248
8.2;CHAPTER 14. MOLECULAR PHARMACOLOGY OF ANTHRACYCLINE ANTITUMOR ANTIBIOTICS;250
8.2.1;I. INTRODUCTION;251
8.2.2;II. CHEMISTRY;252
8.2.3;III. STUDIES ON THE MECHANISM OF ACTION OF ANTHRACYCLINES;255
8.2.4;IV. ANTHRACYCLINE STRUCTURE-ACTIVITY RELATIONSHIPS;271
8.2.5;V. CONCLUSIONS;284
8.2.6;REFERENCES;285
8.3;CHAPTER 15. VINCA ALKALOIDS: MOLECULAR AND CLINICAL PHARMACOLOGY;290
8.3.1;I. INTRODUCTION;290
8.3.2;II. MOLECULAR STRUCTURE;292
8.3.3;III. MOLECULAR PHARMACOLOGY;293
8.3.4;IV. CLINICAL PHARMACOLOGY;296
8.3.5;V. CONCLUSION;301
8.3.6;ACKNOWLEDGMENTS;301
8.3.7;REFERENCES;301
8.4;CHAPTER 16. MOLECULAR PHARMACOLOGY OFALKYLATING AGENTS;304
8.4.1;I. INTRODUCTION;304
8.4.2;II. CHEMISTRY OF THE ALKYLATING REACTIONS;305
8.4.3;III. CLINICALLY EFFECTIVE ALKYLATING AGENTS;306
8.4.4;IV. REACTIONS WITH BIOLOGICAL MOLECULES;312
8.4.5;V. DISCUSSION;318
8.4.6;REFERENCES;318
8.5;CHAPTER 17. MOLECULAR PHARMACOLOGY OF CISPLATIN;320
8.5.1;I. INTRODUCTION;320
8.5.2;II. CHEMISTRY;321
8.5.3;III. BIOCHEMISTRY AND MECHANISM OF ACTION;321
8.5.4;IV. CONCLUSION;326
8.5.5;REFERENCES;326
8.6;CHAPTER 18. METHOTREXATE: MOLECULAR PHARMACOLOGY;328
8.6.1;I. INTRODUCTION;328
8.6.2;II. CHEMISTRY;330
8.6.3;III. MECHANISM OF ACTION AND STRUCTURE-ACTIVITY RELATIONSHIPS;330
8.6.4;IV. TRANSPORT OF METHOTREXATE AND RELATED COMPOUNDS;334
8.6.5;V. MECHANISMS OF RESISTANCE TO FOLATE ANTAGONISTS;334
8.6.6;VI. THE FUTURE FOR FOLATE ANTAGONISTS;336
8.6.7;REFERENCES;337
9;Part III: Clinical Pharmacology of Selected Neoplastic Agents;340
9.1;CHAPTER 19. INTRODUCTION TO CLINICAL PHARMACOLOGY;342
9.1.1;I. INTRODUCTION;342
9.1.2;II. PHARMACOKINETICS;343
9.1.3;III. MATHEMATICAL MODELING;344
9.1.4;IV. CLINICAL CORRELATIONS OF PHARMACOKINETICS;353
9.1.5;V. DISCUSSION;356
9.1.6;REFERENCES;356
9.2;CHAPTER 20. CLINICAL PHARMACOLOGY OF BLEOMYCIN;360
9.2.1;I. INTRODUCTION;360
9.2.2;II. Newer Clinical Pharmacological Assays for Bleomycin;361
9.2.3;III. ABSORPTION;362
9.2.4;IV. DISTRIBUTION;364
9.2.5;V. ELIMINATION;364
9.2.6;VI. CONCLUSIONS;367
9.2.7;REFERENCES;367
9.3;CHAPTER 21. CLINICAL PHARMACOLOGY OF CISPLATIN;368
9.3.1;I. INTRODUCTION;368
9.3.2;II. CISPLATIN PHARMACOKINETICS;368
9.3.3;III. CISPLATIN STABILITY;373
9.3.4;IV. CONCLUSION;373
9.3.5;REFERENCES;373
9.4;CHAPTER 22. METHOTREXATE: CLINICAL PHARMACOLOGY AND THERAPEUTIC APPLICATION;376
9.4.1;I. INTRODUCTION;376
9.4.2;II. PHARMACOLOGY;377
9.4.3;III. CLINICAL APPLICATIONS;380
9.4.4;IV. DISCUSSION;388
9.4.5;REFERENCES;389
9.5;CHAPTER 23. CLINICAL PHARMACOLOGY OF NITROSOUREAS;394
9.5.1;I. INTRODUCTION;394
9.5.2;II. MOLECULAR STRUCTURE;395
9.5.3;III. BIOCHEMISTRY AND METABOLISM;396
9.5.4;IV. CLINICAL PHARMACOLOGY;398
9.5.5;V. DISCUSSION;403
9.5.6;REFERENCES;403
10;INDEX;406